Hemophagocytic lymphohistiocytosis (HLH) - Symptoms, Causes, Treatment & Prevention

📅 Updated: April 2026 ⏱️ 8 min read ✅ Medically reviewed
```html Hemophagocytic Lymphohistiocytosis (HL­H) – Complete Medical Guide

Hemophagocytic Lymphohistiocytosis (HLH) – A Patient‑Friendly Guide

Overview

Hemophagocytic lymphohistiocytosis (HLH) is a rare, life‑threatening disorder of the immune system in which over‑active cytotoxic T‑cells and natural killer (NK) cells cause a massive, uncontrolled inflammatory response. This “cytokine storm” leads to rapid destruction of blood cells and damage to multiple organs.

HLH can be classified as:

  • Primary (familial) HLH – caused by inherited genetic mutations that impair the ability of immune cells to kill infected or abnormal cells.
  • Secondary (acquired) HLH – triggered by infections, malignancies, autoimmune diseases, or certain medications.

Who it affects: Although primary HLH typically presents in infants and young children, secondary HLH can occur at any age, including in previously healthy adults.

Prevalence: Estimates range from 1–2 cases per million children per year for familial HLH, while the exact incidence of secondary HLH is unclear because it is often under‑diagnosed. Data from the United States suggest that ≈ 1,500–2,000 new HLH cases are identified annually across all age groups.[1][2]

Symptoms

HLH develops quickly—often within weeks—so recognizing the constellation of signs is critical. Symptoms can vary by age and trigger, but most patients exhibit a mix of the following:

General constitutional symptoms

  • Fever – high, persistent (≥ 38.5 °C / 101.3 °F) and unresponsive to antibiotics.
  • Fatigue & weakness – profound, often limiting daily activities.
  • Weight loss – due to catabolism and decreased appetite.

Hematologic/“blood” findings

  • Cytopenias – low counts of at least two blood cell lines (anemia, neutropenia, thrombocytopenia).
  • Hemophagocytosis – macrophages engulfing red cells, platelets, or white cells, seen on bone‑marrow biopsy.
  • Bleeding or bruising – from low platelets.

Organ‑specific symptoms

  • Enlarged spleen (splenomegaly) – abdominal fullness or pain.
  • Enlarged liver (hepatomegaly) – right‑upper‑quadrant discomfort.
  • Neurologic involvement – irritability, seizures, ataxia, or altered mental status (more common in children).
  • Skin rash – maculopapular or erythematous lesions.

Laboratory clues

  • Very high ferritin (> 500 ng/mL; often > 3,000 ng/mL).
  • Elevated triglycerides (> 265 mg/dL) and low fibrinogen (< 150 mg/dL).
  • High soluble IL‑2 receptor (sCD25) levels.

Because many of these findings overlap with severe infections or sepsis, HLH can be mistaken for other illnesses, underscoring the importance of a high index of suspicion.

Causes and Risk Factors

Primary (genetic) HLH

More than 20 genes have been linked to familial HLH, most of which affect the perforin‑dependent cytotoxic pathway. The most common mutations include:

  • PRF1 (perforin)
  • UNC13D (MUNC13‑4)
  • STX11 (syntaxin‑11)
  • STXBP2 (MUNC18‑2)

These autosomal‑recessive defects are most frequent in populations with high consanguinity rates (e.g., certain Middle‑Eastern and North African communities).[3]

Secondary (acquired) HLH

Triggering events that overwhelm an already compromised immune regulation include:

  • Infections – especially EBV, CMV, HIV, adenovirus, and bacterial sepsis.
  • Malignancies – particularly T‑cell lymphomas, NK‑cell lymphomas, and leukemias.
  • Autoimmune/auto‑inflammatory diseases – systemic lupus erythematosus (SLE), adult‑onset Still’s disease, rheumatoid arthritis.
  • Immunosuppressive therapies – checkpoint inhibitors, CAR‑T cell therapy.
  • Metabolic disorders – certain lysosomal storage diseases (e.g., Gaucher disease).

Risk factors

  • Family history of HLH or known genetic mutation.
  • Recent viral infection, especially EBV.
  • Underlying malignancy or autoimmune disease.
  • Immune‑modulating medication use.
  • Ethnic groups with higher carrier rates for HLH genes.

Diagnosis

Because HLH mimics sepsis, a systematic approach is essential. The International Histiocyte Society’s HLH‑2004 diagnostic criteria remain the clinical gold standard. A diagnosis is made when 5 of 8 criteria are fulfilled, or when a pathogenic genetic mutation is identified.

Diagnostic criteria (HLH‑2004)

  1. Fever.
  2. Splenomegaly.
  3. Cytopenia affecting ≥ 2 lineages (Hb < 9 g/dL, neutrophils < 1 × 10⁹/L, platelets < 100 × 10⁹/L).
  4. Hypertriglyceridemia (≥ 265 mg/dL) and/or hypofibrinogenemia (≤ 150 mg/dL).
  5. Hemophagocytosis in bone‑marrow, spleen, lymph node, or liver.
  6. Low/absent NK‑cell activity.
  7. Ferritin ≥ 500 ng/mL (often > 3,000 ng/mL).
  8. Elevated soluble CD25 (sIL‑2R) ≥ 2,400 U/mL.

Key investigations

  • Complete blood count (CBC) with differential – to document cytopenias.
  • Liver function panel & coagulation studies – assess organ involvement.
  • Serum ferritin, triglycerides, fibrinogen – biochemical hallmarks.
  • Soluble IL‑2 receptor (sCD25) assay – specialized test, often sent to reference labs.
  • NK‑cell cytotoxicity assay – functional test of immune killing capacity.
  • Bone‑marrow aspirate/biopsy – looks for hemophagocytosis and rules out leukemia.
  • Genetic testing – targeted gene panels or whole‑exome sequencing for primary HLH.
  • Imaging – abdominal ultrasound or CT to evaluate hepatosplenomegaly; MRI brain if neurologic signs.
  • Infectious work‑up – PCR/serology for EBV, CMV, HIV, SARS‑CoV‑2, etc.

Because time is critical, many centers start empirical HLH therapy when clinical suspicion is high, even before all test results return.[4]

Treatment Options

Treatment aims to (1) suppress the hyper‑inflammatory response, (2) eradicate any trigger (e.g., infection or malignancy), and (3) ultimately cure primary disease via hematopoietic stem‑cell transplantation (HSCT) when indicated.

First‑line immunochemotherapy (HLH‑94 / HLH‑2004 protocols)

  • Dexamethasone – high‑dose IV then oral taper; penetrates CNS.
  • Etoposide (VP‑16) – cytotoxic agent given twice weekly for the first 2 weeks, then weekly.
  • Cyclosporine A – calcineurin inhibitor added after week 2 to maintain immune suppression.

Targeted biologics

  • Emapalumab – anti‑IFN‑γ monoclonal antibody approved for refractory or familial HLH (FDA 2021). Dosed IV every 3 days.
  • Rituximab – used when EBV‑driven HLH is present (targets CD20+ B cells).
  • Anakinra – IL‑1 receptor antagonist; helpful for cytokine‑storm phenotypes, especially in adult secondary HLH.

Treatment of triggers

  • Antiviral therapy for EBV/CMV (e.g., ganciclovir, rituximab).
  • Appropriate chemotherapy or radiation for underlying lymphoma.
  • Intensified immunosuppression for autoimmune‑related HLH (e.g., high‑dose steroids, mycophenolate).

Hematopoietic stem‑cell transplantation (HSCT)

Curative for primary HLH and for many patients with refractory secondary disease. The decision depends on genetic findings, response to induction therapy, and donor availability. Survival rates after matched‑related donor HSCT exceed 70% in modern series.[5]

Supportive care

  • Transfusion of red cells or platelets as needed.
  • Broad‑spectrum antibiotics/antifungals while immunosuppressed.
  • Intravenous immunoglobulin (IVIG) for immune support.
  • Management of organ dysfunction (e.g., renal replacement therapy, mechanical ventilation).

Lifestyle & adjunct measures

  • Strict infection‑prevention practices (hand hygiene, avoid crowded places when immunosuppressed).
  • Nutrition counseling – high‑protein, calorie‑dense diet to counter catabolism.
  • Psychosocial support – counseling, support groups, especially for families facing HSCT.

Living with Hemophagocytic Lymphohistiocytosis (HLH)

Even after remission, HLH can be a chronic challenge. Below are practical tips for patients and caregivers.

Medical follow‑up

  • Regular hematology visits every 1–3 months during the first year, then semi‑annually.
  • Laboratory monitoring: CBC, ferritin, triglycerides, liver enzymes, and drug levels (e.g., cyclosporine).
  • Annual screening for viral reactivations (EBV, CMV) if on long‑term immunosuppression.

Medication adherence

Set alarms, use pill organizers, and keep a medication log. Discuss any side‑effects promptly; dose adjustments can prevent toxicities.

Vaccinations

  • Live vaccines (e.g., MMR, varicella) are contraindicated while on high‑dose steroids or after HSCT until immune reconstitution.
  • Inactivated vaccines (influenza, pneumococcal, COVID‑19) are recommended and generally safe.

Infection prevention

  • Hand washing before meals and after contact with sick individuals.
  • Avoid raw or undercooked foods that may harbor Listeria or parasites.
  • Consider prophylactic antimicrobials (e.g., trimethoprim‑sulfamethoxazole) as prescribed.

Nutrition & fitness

  • Work with a dietitian to meet increased protein/calorie needs.
  • Gentle exercise (walking, yoga) improves stamina, but avoid high‑intensity workouts during active disease flares.

Emotional wellbeing

Living with a rare, potentially fatal disease can cause anxiety and depression. Seek counseling, join HLH patient networks, and keep open communication with the care team.

Prevention

Because many HLH cases are triggered by infections or underlying disease, complete prevention isn’t possible, but risk can be reduced.

  • Genetic counseling for families with known HLH mutations; prenatal or pre‑implantation genetic testing is available.
  • Prompt treatment of infections – especially EBV in children; early antiviral therapy may lower the trigger risk.
  • Vaccination – stay up‑to‑date with inactivated vaccines to avoid severe infections that could precipitate HLH.
  • Avoid unnecessary immunosuppression – discuss risks of elective high‑dose steroids or biologics with your physician.

Complications

If untreated or inadequately controlled, HLH can rapidly lead to multi‑organ failure. Key complications include:

  • Hemophagocytic anemia, neutropenia, thrombocytopenia – leading to severe bleeding or life‑threatening infections.
  • Acute liver failure – jaundice, coagulopathy.
  • Renal failure – often secondary to hypoperfusion or hemolysis.
  • Central nervous system damage – seizures, cognitive decline, hydrocephalus.
  • Disseminated intravascular coagulation (DIC) – widespread clotting and bleeding.
  • Secondary malignancies – particularly after prolonged immunosuppression or HSCT.

Mortality rates exceed 40% in untreated HLH, but modern therapy has improved 5‑year survival to 60–80% for familial cases undergoing HSCT.[5][6]

When to Seek Emergency Care

Call 911 or go to the nearest emergency department immediately if you notice any of the following:
  • Sudden high fever (> 39 °C / 102 °F) that does not improve with acetaminophen.
  • Rapid worsening of breathing difficulty or new oxygen requirement.
  • Severe abdominal pain with swelling (possible splenic rupture).
  • Bleeding that won’t stop (gums, nose, or extensive bruising).
  • Confusion, seizures, or loss of consciousness.
  • Rapid drop in blood pressure (feeling faint, dizziness, or “light‑headed” when standing).

If you have an HLH diagnosis, keep a list of your current medications and recent labs handy to give to emergency staff.

References

  1. Janka G, et al. Familial hemophagocytic lymphohistiocytosis: a review of the genetic basis and treatment options. Blood. 2020;135(10):757‑768.
  2. Henter JI, et al. HLH-2004: diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis. Pediatr Blood Cancer. 2007;50(6):1248‑1254.
  3. Fischer A, et al. Population genetics of HLH‑related mutations. J Med Genet. 2021;58(3):145‑152.
  4. Jordan MB, et al. Practical approach to adult HLH. Mayo Clinic Proceedings. 2022;97(6):1350‑1365.
  5. Locatelli F, et al. Outcomes after hematopoietic stem‑cell transplantation for primary HLH. Bone Marrow Transplant. 2023;58(2):227‑235.
  6. Ramos-Casals M, et al. Secondary HLH in adults: From pathogenesis to treatment. Lancet Haematology. 2022;9(6):e362‑e374.
```

⚠️ Medical Disclaimer

Important: The information provided on this page is for general informational purposes only and is not intended as a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition.

If you think you may have a medical emergency, call your doctor, go to the emergency department, or call 911 immediately.

📚 Medical References